Functional complementation of the <i>E</i>. <i>coli tonB</i> mutant impaired in hemin uptake. by HeBin Liao (745873)

Interaction of Biotin with Mg−O Bonds:  Bifunctional Binding and Recognition of Biotin and Related Ligands by the Mg(15-crown-5)²⁺ Unit by Elizabeth R. Sanchez (2987076)

“…This can be understood in terms of the structure of Mg(15-crown-5)(Otf)₂. It shows a pentagonal bipyramidal coordination geometry where the five equatorial positions are occupied by the macrocyclic oxygen donors. …”

Dynamin inhibition reduces apoE secretion from liver cells. by Maaike Kockx (154125)

TKI increases parkin ubiquitination and interaction with Beclin-1. by Irina Lonskaya (429729)

Parkin deletion increases α-Synuclein secretion from the brain into the blood. by Irina Lonskaya (429729)

AZD8055 inhibits the proliferation of CD4⁺ T cells and CD8⁺ T cells in vitro. by Shurong Hu (2634826)

TKI clears α-Synuclein and protects TH⁺ neurons in a parkin-dependent manner. by Irina Lonskaya (429729)

Transcriptional change induced by acidosis and M.tb infection in macrophages. by Ashley M. Whittington (16510641)

Effect of DM, and/or <i>M. charantia</i> on the neurotransmitters levels, acetylcholine (I) and dopamine (II). by Amoura M. Abou-El-Naga (21001524)

Presentation 1_Case Report: Full recovery in severe ParvovirusB19 myocarditis with DCM phenotype: the impact of rASD and PAB.pptx by T. Logeswaran (21495341)

“…The pressure gradient across the PAB ranged from 40 to 45 mmHg, and LVEDD decreased to a mean z-score of +3.5. Within three to six months, LVEDD normalized, and LV-EF increased to a mean of 63% (range: 57%–68%). …”

RecA data. by John L. Kulp III (4389241)

“…The steady state rate of creation of the fluorescence is plotted on the y-axis in relative fluorescence units (RFU). The addition of a RecA inhibitor decreases the rate of production of RFUs in a concentration dependent manner. 6-Hydroxydopamine inhibits RecA with an IC₅₀ of 23 uM. …”

PIK3C3 promotes <i>Shigella flexneri</i> cell-to-cell spread through resolution of VLPs into DMVs. by Steven J. Rolland (21376879)

Effect of dynamin inhibitors on microtubule morphology and tubulin acetylation. by Maaike Kockx (154125)

Foxf1 promotes expression of a Wnt signaling reporter. by Ugo Coppola (3524945)

“…<i>Xla-Sia</i>:<i>GFP</i> embryos at 34 hpf. (<b>A’-C’</b>) <i>7xTcf</i>.<i>Xla-Sia</i>:<i>GFP</i> (green), (<b>A”-C”</b>) Mhc (red), and (<b>A”’-C”’</b>) Amhc (blue). …”

Functional analyses of ARHGAP11A-knockdown HCT116 human colon cancer cells. by Yoshinori Kagawa (503599)

“…(I) <i>In vivo</i> siRNA treatment of HCT116 tumors. Control HCT116 cells (5.0×10⁶) were implanted into NOD/SCID mice, and 1 week later were treated with PBS (<i>black filled</i> circles), atelocollagen (<i>black filled</i> triangles), scrambled control siRNA plus atelocollagen (<i>black filled</i> squares), or two siRNAs (#1 and #2) against ARHGAP11A plus atelocollagen (<i>red open</i> circles and squares, respectively). …”

Loss of FlnA and Fmn2 leads to a defect in cell proliferation along the ventral thoracic wall. by Gewei Lian (523268)

“…</b> The number of BrdU or Ki67 positive cells in the ventral midline of null FlnA and null FlnA+Fmn2 embryos was decreased by more than 50% in comparison with those in WT embryo (WT vs null FlnA *** = p <0.0002, WT vs null FlnA+Fmn2 *** = p <0.0008). …”

Table_1_Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.do... by Roger H. Kobayashi (6291587)

“…The incidence of site reactions decreased with successive infusions.</p><p>Conclusion: The new 16.5% SCIG octanorm was shown to be efficacious in preventing infections in PIDs, and was well tolerated.…”

Table_2_Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.do... by Roger H. Kobayashi (6291587)

“…The incidence of site reactions decreased with successive infusions.</p><p>Conclusion: The new 16.5% SCIG octanorm was shown to be efficacious in preventing infections in PIDs, and was well tolerated.…”

Table_2_Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.do... by Roger H. Kobayashi (6291587)

“…The incidence of site reactions decreased with successive infusions.</p><p>Conclusion: The new 16.5% SCIG octanorm was shown to be efficacious in preventing infections in PIDs, and was well tolerated.…”

Table_1_Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.do... by Roger H. Kobayashi (6291587)

“…The incidence of site reactions decreased with successive infusions.</p><p>Conclusion: The new 16.5% SCIG octanorm was shown to be efficacious in preventing infections in PIDs, and was well tolerated.…”